{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:39:07Z","timestamp":1792607947597,"version":"4.5.0"},"reference-count":34,"publisher":"Association for Research in Vision and Ophthalmology (ARVO)","issue":"11","license":[{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trans. Vis. Sci. Tech."],"published-print":{"date-parts":[[2024,11,13]]},"DOI":"10.1167\/tvst.13.11.14","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T11:41:49Z","timestamp":1731498109000},"page":"14","source":"Crossref","is-referenced-by-count":15,"title":["Ocular Pharmacokinetics of Faricimab Following Intravitreal Administration in Patients With Retinal Disease"],"prefix":"10.1167","volume":"13","author":[{"given":"Cheikh","family":"Diack","sequence":"first","affiliation":[{"name":"Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonid","family":"Gibiansky","sequence":"additional","affiliation":[{"name":"QuantPharm LLC, North Potomac, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Jaminion","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Gibiansky","sequence":"additional","affiliation":[{"name":"QuantPharm LLC, North Potomac, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Gaudreault","sequence":"additional","affiliation":[{"name":"JJG Pharma Consulting, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrijn","family":"Bogman","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Cosson","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27","reference":[{"key":"bib1","doi-asserted-by":"publisher","first-page":"e1221","DOI":"10.1016\/S2214-109X(17)30393-5","article-title":"Global causes of blindness and distance vision impairment 1990\u20132020: a systematic review and meta-analysis","volume":"5","author":"Flaxman","year":"2017","journal-title":"Lancet Glob Health"},{"key":"bib2","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.preteyeres.2008.05.001","article-title":"Vascular endothelial growth factor in eye disease","volume":"27","author":"Penn","year":"2008","journal-title":"Prog Retin Eye Res"},{"key":"bib3","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1038\/s41433-018-0021-7","article-title":"Clinical pharmacology of intravitreal anti-VEGF drugs","volume":"32","author":"Fogli","year":"2018","journal-title":"Eye (Lond)"},{"key":"bib4","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"bib5","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intra-vitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"bib6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"key":"bib7","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s00417-017-3647-4","article-title":"Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases","volume":"255","author":"Lanzetta","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"bib8","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1007\/s00417-019-04404-0","article-title":"Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study","volume":"257","author":"Augsburger","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"bib9","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.ophtha.2019.03.023","article-title":"Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-a with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial","volume":"126","author":"Sahni","year":"2019","journal-title":"Ophthalmology"},{"key":"bib10","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.15252\/emmm.201505889","article-title":"Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases","volume":"8","author":"Regula","year":"2016","journal-title":"EMBO Mol Med"},{"key":"bib11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/IAE.0000000000003003","article-title":"The angiopoietin\/Tie pathway in retinal vascular diseases: a review","volume":"41","author":"Heier","year":"2021","journal-title":"Retina"},{"key":"bib12","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/s41433-020-01377-x","article-title":"Angiopoietin\/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data","volume":"35","author":"Joussen","year":"2021","journal-title":"Eye (Lond)"},{"key":"bib13","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier","year":"2022","journal-title":"Lancet"},{"key":"bib14","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials","volume":"399","author":"Wykoff","year":"2022","journal-title":"Lancet"},{"key":"bib15","first-page":"2185","article-title":"Faricimab rapidly improves fluid parameters in patients with nAMD","volume":"64","author":"Querques","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib16","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","article-title":"TENAYA and LUCERNE: 2-year results from the phase 3 nAMD trials of faricimab with treat-and-extend dosing in year 2","volume":"131","author":"Khanani","year":"2024","journal-title":"Ophthalmology"},{"key":"bib17","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ophtha.2023.12.026","article-title":"Faricimab treat-and-extend for diabetic macular edema: two-year results from the randomized phase 3 YOSEMITE and RHINE trials","volume":"131","author":"Wong","year":"2024","journal-title":"Ophthalmology"},{"key":"bib18","doi-asserted-by":"publisher","first-page":"100076","DOI":"10.1016\/j.xops.2021.100076","article-title":"TENAYA and LUCERNE: rationale and design for the phase 3 clinical trials of faricimab for neovascular age-related macular degeneration","volume":"1","author":"Khanani","year":"2021","journal-title":"Ophthalmol Sci"},{"key":"bib19","doi-asserted-by":"publisher","first-page":"100111","DOI":"10.1016\/j.xops.2021.100111","article-title":"YOSEMITE and RHINE: phase 3 randomized clinical trials of faricimab for diabetic macular edema: study design and rationale","volume":"2","author":"Eter","year":"2022","journal-title":"Ophthalmol Sci"},{"key":"bib20","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.oret.2017.03.003","article-title":"Phase I trial of anti-vascular endothelial growth factor\/anti-angiopoietin 2 bispecific antibody RG7716 for neovascular age-related macular degeneration","volume":"1","author":"Chakravarthy","year":"2017","journal-title":"Ophthalmol Retina"},{"key":"bib21","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1001\/jamaophthalmol.2020.2685","article-title":"Safety and efficacy of different doses and regimens of faricimab vs ranibizumab in neovascular age-related macular degeneration: the AVENUE phase 2 randomized clinical trial","volume":"138","author":"Sahni","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"bib22","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1001\/jamaophthalmol.2020.2699","article-title":"Efficacy of every four monthly and quarterly dosing of faricimab vs ranibizumab in neovascular age-related macular degeneration: the STAIRWAY phase 2 randomized clinical trial","volume":"138","author":"Khanani","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"bib23","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1023\/A:1012299115260","article-title":"Ways to fit a PK model with some data below the quantification limit","volume":"28","author":"Beal","year":"2001","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"bib24","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1021\/acs.molpharmaceut.5b00849","article-title":"A mechanistic model of the intravitreal pharmacokinetics of large molecules and the pharmacodynamic suppression of ocular vascular endothelial growth factor levels by ranibizumab in patients with neovascular age-related macular degeneration","volume":"13","author":"Hutton-Smith","year":"2016","journal-title":"Mol Pharm"},{"key":"bib25","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1023\/A:1011555016423","article-title":"Evaluating pharmacokinetic\/pharmacodynamic models using the posterior predictive check","volume":"28","author":"Yano","year":"2001","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"bib26","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10928-007-9081-1","article-title":"Extensions to the visual predictive check to facilitate model performance evaluation","volume":"35","author":"Post","year":"2008","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"bib28","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1167\/iovs.12-10260","article-title":"Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach","volume":"54","author":"Xu","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib29","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/clpt.2008.170","article-title":"Monoclonal antibody pharmacokinetics and pharmacodynamics","volume":"84","author":"Wang","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"bib30","doi-asserted-by":"publisher","first-page":"643","DOI":"10.4155\/tde.11.19","article-title":"Flip-flop pharmacokinetics \u2013 delivering a reversal of disposition: challenges and opportunities during drug development","volume":"2","author":"Yanez","year":"2011","journal-title":"Ther Deliv"},{"key":"bib31","first-page":"695","article-title":"Ocular half-life of intravitreal biologics in humans and other species: meta-analysis and model-based prediction","volume":"17","author":"Caruso","year":"2020","journal-title":"Mol Pharm"},{"key":"bib32","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1136\/pgmj.2005.040857","article-title":"Ageing changes in the eye","volume":"82","author":"Salvi","year":"2006","journal-title":"Postgrad Med J"},{"key":"bib33","doi-asserted-by":"publisher","first-page":"ORSF23","DOI":"10.1167\/iovs.13-12711","article-title":"Anatomic alterations in aging and age-related diseases of the eye","volume":"54","author":"Grossniklaus","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib34","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1001\/jamaophthalmol.2022.5403","article-title":"Immunogenicity with ranibizumab biosimilar SB11 (Byooviz) and reference product Lucentis and association with efficacy, safety, and pharmacokinetics: a post hoc analysis of a phase 3 randomized clinical trial","volume":"141","author":"Bressler","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"bib27","volume-title":"NONMEM Users Guides. (1989\u20132009)","author":"Beal","year":"2009"}],"container-title":["Translational Vision Science & Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/tvst.arvojournals.org\/article.aspx?articleid=2802228","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T11:41:51Z","timestamp":1731498111000},"score":1,"resource":{"primary":{"URL":"https:\/\/tvst.arvojournals.org\/article.aspx?articleid=2802228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,13]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11,4]]}},"URL":"https:\/\/doi.org\/10.1167\/tvst.13.11.14","relation":{},"ISSN":["2164-2591"],"issn-type":[{"value":"2164-2591","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,13]]}}}